Invivyd (IVVD) Share-based Compensation (2020 - 2026)
Invivyd's (IVVD) quarterly Share-based Compensation came in at $30.2 million in Q2 2026, up 42.48% on a YoY basis from $21.2 million in Q2 2025, and up 1078.95% quarter-over-quarter from $2.6 million in Q4 2025.
Analysis
Invivyd (IVVD) Share-based Compensation (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Share-based Compensation for 7 consecutive years, with $30.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Share-based Compensation rose 42.48% year-over-year to $30.2 million; the trailing twelve-month figure through Jun 2026 stood at $30.2 million (up 42.48% YoY), and the FY2025 full-year result was $21.4 million, up 7.9% from the prior year.
- Share-based Compensation improved to $30.2 million in Q2 2026 per IVVD's latest filing, from $2.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $30.2 million in Q2 2026 and bottomed at $2.6 million in Q4 2025.
- Historically, Share-based Compensation has averaged $18.5 million across 5 years, with a median of $21.4 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 3262.51% in 2022, then slipped 29.63% in 2024.
- Over 5 years, Share-based Compensation stood at $5.9 million in 2022, then slipped by 26.44% to $4.3 million in 2023, then retreated by 29.63% to $3.1 million in 2024, then retreated by 16.13% to $2.6 million in 2025, then surged by 1078.95% to $30.2 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $30.2 million, $2.6 million, and $21.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 30.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.23 Mn |
| Dec 31, 2025 | 2.56 Mn |
| Sep 30, 2025 | 21.32 Mn |
| Jun 30, 2025 | 21.22 Mn |
| Mar 31, 2025 | 23.01 Mn |
| Dec 31, 2024 | 3.06 Mn |
| Sep 30, 2024 | 21.88 Mn |
| Jun 30, 2024 | 25.03 Mn |
| Mar 31, 2024 | 26.36 Mn |
| Dec 31, 2023 | 4.34 Mn |
| Sep 30, 2023 | 22.05 Mn |
| Jun 30, 2023 | 21.82 Mn |
| Mar 31, 2023 | 23.88 Mn |
| Dec 31, 2022 | 5.91 Mn |
| Sep 30, 2022 | 21.40 Mn |
| Jun 30, 2022 | 19.94 Mn |
| Mar 31, 2022 | 19.74 Mn |
| Dec 31, 2021 | 7.86 Mn |
| Sep 30, 2021 | 17.46 Mn |
| Jun 30, 2021 | 14.93 Mn |